Revenue segments as reported by the company.

Diabetes

Oncology

Immunology

Neuroscience

Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Marketing, selling and administrative

Acquired in-process research and development

Asset impairment, restructuring and other special charges

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Eli Lilly

Cialis, ia a competitor to Pfizer's blockbuster Viagra for erectile dysfunction. Cialis maintains an active period of 36 hours.

Cialis

Cymbalta is a serotonin-norepinephrine reuptake inhibitor used predominantly in the treatment of major depressive disorders and generalized anxiety disorder, ranks with Prozac as one of the most financially successful pharmaceuticals in industry history. It is also used in the treatment of fibromyalgia, neuropathy, chronic pain and osteoarthritis.

Cymbalta

Gemzar is a treatment of pancreatic cancer. Gemzar is commonly used in the treatment of pancreatic cancer, usually in coordination with 5-FU chemotherapy and radiology. Gemzar also is routinely used in the treatment of non-small cell lung cancer.

Gemzar

Methadone is an analgesic used frequently in the treatment of heroin, opium and other opioid and narcotic drug addictions.

Methadone

Prozac was one of the first therapies in its class to treat clinical depression by blocking the uptake of serotonin within the human brain. It is prescribed to more than fifty-four million people worldwide.

Prozac

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Eli Lilly reports robust Q4 earnings, eyes growth in innovative therapies

Eli Lilly's Q4 2022 earnings call highlighted strong financial performance, pipeline advancements, and strategic initiatives for future growth.
The company's focus on innovation, FDA approvals, and market expansion underscores its commitment to addressing unmet medical needs and driving shareholder value.
Challenges in physician education, obesity treatment development, and market access present areas for strategic focus and investment for sustained growth.
Opportunities in expanding manufacturing capacity, engaging with payers, and capitalizing on consumer interest in obesity treatments position Lilly for continued success in 2023.

Eli Lilly reports robust Q1 growth amidst capacity challenges

Eli Lilly's Q1 2023 performance reflects strong revenue growth and strategic investments in new products and facilities.
While facing challenges in capacity and supply pressure, the company's focus on pipeline advancements and market opportunities positions it for future growth.
Opportunities in international markets, cardiovascular trials, and product promotion present avenues for continued expansion and revenue growth.
Overall, Eli Lilly's financial performance, product strengths, and strategic initiatives demonstrate a resilient and growth-focused approach.

Eli Lilly reports robust Q2 earnings, eyes growth through innovation

Eli Lilly's Q2 earnings call showcased strong financial performance, revenue growth, and advancements in its pipeline, driven by key products and strategic investments.
The company faces challenges in managing increased expenses, supply chain constraints, and regulatory considerations, requiring strategic decision-making and operational agility.
Opportunities lie in expanding market access, leveraging innovative treatments like tirzepatide, and enhancing manufacturing capabilities to drive future growth and competitive advantage.
Overall, Lilly's focus on innovation, market expansion, and addressing health needs positions it well for sustained growth and leadership in the pharmaceutical industry.

Eli Lilly posts robust Q3 results, eyes expansion and commercial growth

Eli Lilly (LLY) showcased strong financial performance and pipeline advancements in Q3 2023.
Challenges include supply restrictions and pricing decisions, but opportunities lie in expansion plans and commercial coverage ramp-up.
Investors advised to focus on guidance range for insights into 2024 expectations.

Eli Lilly posts robust Q4 results, eyes global expansion opportunities

Eli Lilly's strong financial performance in Q4 2023, driven by revenue growth and operational efficiency, sets a solid foundation for future growth.
The company's strategic acquisitions, global expansion plans, and focus on innovation position it well for continued success and market leadership.
Challenges in drug development and manufacturing require careful navigation, but opportunities in new drug trials and market expansion offer avenues for growth.
Overall, Eli Lilly's 2023 was marked by productivity and anticipation of sustained momentum in 2024, reflecting a positive outlook for the company.

Eli Lilly reports robust Q1 growth, eyes pipeline opportunities

Eli Lilly's Q1 performance showcased strong revenue growth, driven by new products and global market expansion.
While facing challenges like low Zepbound volume and manufacturing complexities, Lilly's strengths in innovation and market presence position it well for growth.
Opportunities in pipeline advancements, differentiation in drug portfolios, and potential Alzheimer's treatments signal a promising future for the company.
Overall, Eli Lilly's strategic focus on growth, innovation, and market expansion sets a positive trajectory for continued success.

Eli Lilly reports stellar Q3 results, eyes global expansion opportunities

Eli Lilly's Q3 performance reflects robust revenue growth, driven by new products and strategic investments, positioning the company for continued success.
Key pipeline advancements and revenue guidance raise optimism for future growth, with a focus on global scaling and market expansion initiatives.
Challenges in patient adherence and treatment efficacy are being addressed, while opportunities in market penetration and revenue growth are actively pursued.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Eli Lilly announced impressive Q1 2024 financial results, with revenue surging by 26% YoY and exceeding expectations for earnings per share. The company raised its full-year 2024 revenue guidance and adjusted earnings per share guidance. While facing challenges with the price of its stock and supply chain issues, Eli Lilly anticipates significant increases in shipment volumes in the second half of 2024.

Eli Lilly's Growth And Challenges: A Cautious Buy

Novo Nordisk

Eli Lilly and Novo Nordisk have generated incredible returns for investors in the past few years. The surging popularity of their weight loss treatments has produced a lot of bullishness.

This Is the Biggest Risk for Eli Lilly and Novo Nordisk Investors

Intuitive Surgical

Universal Health Services

Vertex Pharmaceuticals

Eli Lilly is in a buy zone, while weight-loss drug rival Novo Nordisk just forged a lower entry.

S&P 500 Giants Lead Five Healthy Stocks Near Buy Points

Data demonstrated promising monotherapy activity with olomorasib across a range of KRAS G12C-mutant solid tumors, including non-small cell lung cancer, and a tolerability profile in combination with pembrolizumab that is well-suited to first-line lung cancer development INDIANAPOLIS , June 1, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced updated data from the Phase 1/2 clinical trial evaluating olomorasib as a monotherapy in patients with KRAS G12C-mutant advanced solid tumors and in combination with Merck's anti-PD-1 therapy KEYTRUDA® (pembrolizumab) in patients with KRAS G12C-mutant advanced non-small cell lung cancer (NSCLC). Olomorasib is an investigational, oral, potent, and highly selective second-generation inhibitor of the KRAS G12C protein.

Updated Data from the Phase 1/2 Study of Olomorasib in KRAS G12C-Mutant Advanced Solid Tumors Presented at the 2024 ASCO® Annual Meeting

Marvell Technology

Uber

Although there is no hard-and-fast rule about what constitutes a blue-chip stock, they all tend to have certain qualities. They are large, financially stable companies that have been through numerous business and economic cycles that proved their worth in the end.

Aristocrats in Disguise: 3 Blue-Chip Stocks With Stealth Growth Potential

Advanced Micro Devices

Broadcom

Disney

Lithium Americas Argentina Corp

NVIDIA

Institutional investors represent the so-called big money that wields significant influence over the stock market. That influence manifests in many ways.

Institutional Bets: 7 Stocks the Big Money Will Send Higher This Year

Lilly (LLY) reported earnings 30 days ago. What's next for the stock?

Why Is Lilly (LLY) Up 4.5% Since Last Earnings Report?

Chipotle

CrowdStrike

Fair Isaac

Robinhood

Palantir Technologies

If you're wondering which overvalued blue-chip stocks to ditch right now, look no further. The best investors pay attention to a stock's valuation.

Blue-Chip Bubble Trouble: 7 Stocks to Short as Valuations Stretch to the Limit

Eli Lilly sells two of the most sought-after treatments -- those prescribed for weight management. Mounjaro and Zepbound are driving double-digit earnings growth at the big pharma company.

Could Eli Lilly Be the Next to Join the Trillion-Dollar Club?

New  $6.5 million commitment will help strengthen systems to improve health outcomes across resource-limited areas in India GENEVA , May 29, 2024 /PRNewswire/ -- During the World Health Assembly today, Eli Lilly and Company (NYSE: LLY) announced it will donate $6.5 million to the United States Fund for UNICEF to expand UNICEF's work to improve the health outcomes of millions of children and youth at risk of noncommunicable diseases (NCDs) living in resource-limited settings in India. This will bring the company's total commitment since 2022 to more than $20 million.

Lilly, UNICEF expand support to help millions of young people at risk of noncommunicable diseases

INDIANAPOLIS , May 28, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will participate in the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024. Patrik Jonsson, executive vice president, president of Lilly Diabetes and Obesity, and president of Lilly USA, will participate in a fireside chat at 4 p.m.

Lilly to Participate in Goldman Sachs 45th Annual Global Healthcare Conference

McDonald's

Visa

Investors who buy dividend stocks do so for the current income and the potential for that income to grow in the future. There are a couple of ways to ensure that happens.

The Dividend Acceleration Squad: 3 Stocks With Rapidly Rising Yields

As millions seek access to weight-loss drugs from Novo Nordisk and Eli Lilly , increasing supplies, possible wider usage and a growing number of would-be rivals are leading some experts to raise annual global sales forecasts for the treatments to about $150 billion by the early 2030s.

Weight-loss drug forecasts jump to $150 billion as supply grows

Eli Lilly stock could reach $1,001 per share, according to a Wall Street analyst from BMO Capital. Tirzepatide sales are off the charts but could be much higher if not for supply constraints.

Soaring Eli Lilly Stock Could Climb Another 24% According to a Wall Street Analyst. Is the Stock a Buy Now?

Since 2020, Eli Lilly (LLY) has committed more than $18 billion to building new manufacturing sites as well as updating existing manufacturing facilities.

Eli Lilly (LLY) to Ramp Up Indiana Site for Mounjaro, Zepbound

Eli Lilly's shares reached new all-time highs after the company increased full-year revenue and EPS guidance. The company's growth is currently supply-constrained and the growth of tirzepatide in the near- and possibly medium-term should only be limited by the quantities it can produce. Eli Lilly's competitive position in the obesity market is discussed in today's article along with the potential for growth acceleration in 2025 and 2026 versus current expectations for moderating growth rates.

Eli Lilly: Addressing Supply Challenges Should Accelerate Growth

Pfizer

Vertex Pharmaceuticals is in the midst of a major diversification plan. Eli Lilly's medicines for diabetes and obesity are incredibly hot sellers.

Got $500? 3 Pharma Stocks to Buy and Hold Forever

Some analysts estimate that anti-obesity medications could grow into a $100 billion industry by the end of the decade. Companies including Calibrate, Ro and WeightWatchers are looking to capitalize on the GLP-1 boom by launching weight loss programs around medications like Ozempic and Wegovy.

How digital health companies are capitalizing on the GLP-1 boom

Eli Lilly is just getting started with its powerful obesity drug and a loaded pipeline. It's not too late to invest in scorching-hot Novo Nordisk.

3 High-Flying Stocks That Could Soar Even More

Eli Lilly & Co. said Friday that it has more than doubled its investment in a Lebanon, Ind., site to boost manufacturing capacity for its popular weight-loss drug Zepbound and diabetes treatment Mounjaro.

Eli Lilly to spend $5.3 billion to boost Zepbound, Mounjaro manufacturing

Eli Lilly said on Friday it has invested another $5.3 billion in its new Lebanon, Indiana manufacturing plant, more than doubling its previous investment, as it scrambles to meet soaring demand for its weight-loss and diabetes drugs.

Lilly invests further $5.3 bln in new Indiana site as obesity drug demand soars

Eli Lilly said it is investing another $5.3 billion in a manufacturing plant in Lebanon, Indiana to expand the supply of its highly popular weight loss drug Zepbound, diabetes treatment Mounjaro and other medicines in its pipeline. Demand for Zepbound and Mounjaro has far outpaced supply over the last year, spurring shortages in the U.S. and forcing the pharmaceutical giant to invest heavily to scale up its manufacturing.

Eli Lilly to invest another $5.3 billion in Indiana plant to expand Mounjaro, Zepbound supply

Largest investment in active pharmaceutical ingredient manufacturing of synthetic medicines in U.S. history Since 2020, the company has committed more than $18 billion to build, upgrade and acquire facilities in the U.S. and Europe INDIANAPOLIS , May 24, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that it has more than doubled its investment in its Lebanon, Indiana, manufacturing site with a new $5.3 billion commitment, increasing the company's total investment in this site from $3.7 billion  to $9 billion. This expansion will enhance Lilly's capacity to manufacture active pharmaceutical ingredients (API) for Zepbound® (tirzepatide) injection and Mounjaro® (tirzepatide) injection so that more adults with chronic diseases like obesity and type 2 diabetes may benefit from these important treatments.

Lilly Increases Manufacturing Investment to $9 Billion at Newest Indiana Site to Boost API Production for Tirzepatide and Pipeline Medicines

The outlay to expand an Indiana production site, combined with a previous $3.7 billion commitment, is the largest manufacturing investment in company history.

Eli Lilly to Spend $5.3 Billion to Make More Mounjaro, Zepbound

Amazon

Home Depot

Microsoft

Netflix

Exxon Mobil

Stocks to buy if the market fails: that's the other side of the coin to the search query, is the market overvalued right now? Pop that question into your favorite search engine and you're bound to find endless opinions.

News for Eli Lilly Stock (LLY)